top of page

Journal: Clinics and Research in Hepatology and Gastroenterology

First author: Rim Bourguiba

Country of study: France and Tunisia

CEREMAIA Tenon author(s): Marion Delplanque, Catherine Grandpeix-Guyodo, Léa Savey, Sophie Georgin-Lavialle

Reference: Bourguiba R, Delplanque M, Grandpeix-Guyodo C, Boursier G, Savey L, Cuisset L, Georgin-Lavialle S. When to suspect monogenic autoinflammatory diseases in patients with digestive symptoms? Clinics and Research in Hepatology and Gastroenterology. 2026;50:102820.

DOI: https://doi.org/10.1016/j.clinre.2026.102820


When to suspect monogenic autoinflammatory diseases in patients with digestive symptoms?

5 key points:

  • Some rare autoinflammatory diseases can cause abdominal pain, diarrhoea, digestive inflammation or symptoms that resemble inflammatory bowel disease.

  • Familial Mediterranean fever is the most common monogenic autoinflammatory disease and should be considered in people of Mediterranean origin with repeated inflammatory abdominal pain.

  • Associated signs such as recurrent fever, mouth ulcers, skin rashes, joint pain, macrocytic anaemia or family history should raise suspicion of an autoinflammatory cause.

  • Diagnosis is based on clinical assessment, inflammation markers, sometimes IL-18 measurement, and appropriate genetic testing.

  • Earlier diagnosis can reduce diagnostic delay, guide treatment and help prevent complications such as AA amyloidosis.


Introduction

Systemic autoinflammatory diseases are rare conditions caused by abnormal activation of the innate immune system, the body’s first line of defence. They can cause flares of inflammation with fever, pain, skin involvement, joint symptoms or digestive problems. In some patients, digestive symptoms are the main feature and may look like inflammatory bowel disease, such as Crohn’s disease.


Methods

This article is a narrative review of the medical literature. The authors describe the main monogenic autoinflammatory diseases that may cause digestive symptoms and highlight situations in which gastroenterologists should consider these diagnoses.


Results

Several diseases can cause abdominal pain, diarrhoea, colitis, digestive ulcers or inflammation that resembles Crohn’s disease. Familial Mediterranean fever is the most common, especially in people of Mediterranean origin. Other conditions include TRAPS, Mevalonate kinase deficiency, cryopyrin-associated diseases, VEXAS syndrome, A20 haploinsufficiency, and diseases linked to RIPK1, RELA, NFKB1, JAK1, STAT, PSTPIP1, ADA2, LACC1, XIAP or PLCG2. Warning signs include recurrent fever, unexplained inflammation in blood tests, mouth ulcers, skin rashes, joint pain, family history, Mediterranean origin, macrocytic anaemia or poor response to usual treatments for inflammatory digestive diseases.


Discussion

The article emphasizes that not all digestive inflammation should automatically be considered a typical bowel disease. An autoinflammatory disease may mimic inflammatory bowel disease, coexist with it, or be revealed by unusual digestive symptoms. Useful investigations may include inflammation markers, endoscopy, specific biomarkers such as IL-18, and above all appropriate genetic testing, ideally discussed with expert centres.


Conclusion

Rare autoinflammatory diseases should be considered when digestive symptoms are inflammatory, unexplained, recurrent or resistant to usual treatments. Early diagnosis can lead to more appropriate care, often using treatments that target inflammation, and may help prevent complications such as AA amyloidosis.


 
 
 
CEREMAIA Tenon

In 2025, together with the team of the CEREMAIA Reference Center (Tenon Hospital, AP-HP / Sorbonne University), within the FAI2R network and the European Reference Network ERN RITA, we carried out extensive work focused on:


Familial Mediterranean Fever (FMF) and pyrin-associated diseases,

VEXAS syndrome, a prototype of hemato-inflammatory diseases,

AA amyloidosis and other rarer autoinflammatory diseases.


🔬 FMF and pyrin

We contributed to the update of the international EULAR/PReS recommendations for FMF, which incorporate recent advances regarding colchicine resistance and the use of biologic therapies (published in Annals of the Rheumatic Diseases, 2025).


Several studies based on the adult cohort of our reference center explored the following aspects: iron deficiency, liver involvement, FMF onset after the age of 65, the optimal daily dose of colchicine, and patients’ and prescribers’ perceptions of colchicine treatment.


We also conducted biological and genetic research on variants of the MEFV gene and pyrin-associated diseases, as well as on the role of IL-18 as a monitoring biomarker and as a specific signature of diseases involving the pyrin inflammasome.


🧬 VEXAS syndrome

In collaboration with the French VEXAS group and the MINHEMON club:


international reviews and recommendations were developed to structure the diagnosis and management of VEXAS syndrome, including a consensual definition of “flares,” infectious risks, and therapeutic strategies;


studies focused on specific organ involvement (kidney, nervous system, erythroblastopenia), as well as a multicenter study on VEXAS in women and across different ethnic backgrounds.


🧩 AA amyloidosis and other rare autoinflammatory diseases


We participated in a systematic review on AA amyloidosis in inflammatory rheumatic diseases, highlighting the importance of long-term strict control of inflammation.


We authored literature reviews on autoinflammatory actinopathies, A20 haploinsufficiency, and undifferentiated autoinflammatory diseases.


We also published work on diagnostic delay and the clinical presentation of cryopyrin-associated periodic syndromes (CAPS) in adulthood.


🧠 Therapeutic patient education programs

We continued the deployment of our three therapeutic education programs dedicated to AA amyloidosis, cryopyrinopathies (CAPS), and FMF. These programs aim to help patients and their relatives better understand the disease, treatments, monitoring, and warning signs.

In 2025, we notably led a session dedicated to CAPS during the weekend organized in July by the Muckle-Wells / CINCA association, in close collaboration with patient associations.


🎥 Patient webinars and online information

We launched a series of informational webinars for patients and their relatives on FMF, as well as educational videos on rare autoinflammatory diseases (AA amyloidosis, VEXAS syndrome, etc.), freely available on the CEREMAIA Tenon YouTube channel: CEREMAIA Tenon – Patient Webinars. These formats allow us to translate research findings and recommendations into practical messages for patients’ daily lives.


  • All of this work shares a common goal:

  • to better characterize these rare diseases,

  • to refine diagnostic and monitoring strategies,


and ultimately, to provide more personalized and safer care for patients.


We warmly thank the patients, healthcare teams, colleagues from rare disease networks, and international partners for their commitment.


For those who would like to access specific articles in more detail, please feel free to contact us via private message or by email at:

 
 
 

English title: Epidemiology and clinical presentation of kidney amyloidosis have changed over the past three decades: a nationwide population-based study

First author: Hilde J. Vasstrand

Journal : BMC Nephrology

Reference : BMC Nephrol. 2025 Jun 2;26(1):272.

Article summarized by: Dr Catherine Grandpeix-Guyodo


Renal amyloidosis in Norway: how the disease has evolved over 30 years

Introduction:

Amyloidoses are diseases related to protein deposits in the form of amyloid fibrils. Protein typing helps understand the presentation of the disease, its progression, prognosis, and allows treatment adaptation. Early diagnosis of kidney amyloidosis is essential for treatment optimization and prognosis improvement. This Norwegian nationwide study conducted over 30 years explores changes in the epidemiology and clinical presentation of kidney amyloidosis to raise awareness about these conditions.

Patients and methods: Over a 30-year period, 479 patients with amyloidosis on kidney biopsy were identified in the registries, including 209 AA amyloidoses (SAA protein deposits) and 270 non-AA amyloidoses (mainly AL amyloidoses from immunoglobulin light chain deposits). Patient records were studied and cases were separated into AA amyloidosis and non-AA amyloidosis.


Results:

The frequency of renal amyloidosis was stable over time (4% of kidney biopsies), but AL amyloidosis became the predominant form of non-AA amyloidoses with a frequency increasing from 1.9% to 2.8% of kidney biopsies (p = 0.014). In parallel, the proportion of AA amyloidosis decreased from 2.6% to 1.3% (p < 0.001), due to the reduction in amyloidoses secondary to inflammatory rheumatic diseases, partly offset by AA amyloidoses secondary to drug injections.

Advances in typing amyloid deposits significantly reduced undetermined amyloidoses (p < 0.001) and led to more precise diagnoses. Clinical presentations were varied, but proteinuria was present in 94% of patients. Nephrotic syndrome was noted more frequently in patients with non-AA amyloidosis (70%) than in those with AA amyloidosis (51%). Kidney function was better preserved in non-AA amyloidoses (median GFR 53 ml/min/1.73 m²) than in AA amyloidoses (median GFR 27 ml/min/1.73 m²). Patients with AA amyloidosis were younger (p < 0.001) and more often hypertensive (53% versus 38%, p < 0.001).

Regarding patients developing AA amyloidosis following drug injection, they were younger, more often male, and presented more advanced kidney disease with half in end-stage kidney disease.

Recently, the authors noted that patients with non-AA amyloidosis had better albumin, hemoglobin, and ESR levels (p < 0.05). Additionally, the proportion of non-AA amyloidosis with end-stage kidney disease dropped from 26.8% to 8.7% (p = 0.005), which could indicate earlier diagnoses.


Conclusion:

There have been changes in the epidemiology of kidney amyloidosis in Norway over the past 30 years. The rate of non-AA amyloidosis in biopsies has increased, and certain indicators suggest that diagnosis is made earlier. Amyloid typing has improved, which is reflected in more precise diagnoses with a decrease in undetermined forms. AA amyloidoses related to inflammatory rheumatic diseases have significantly decreased, but the increase in AA amyloidoses in patients who inject drugs is becoming a growing problem.

Awareness of amyloidoses remains necessary, especially during this period when epidemiology is changing with, as a consequence, the possibility of changes in clinical presentation and therapeutic needs.

 
 
 
bottom of page